Top-Rated StocksTop-RatedNASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free FDMT Stock Alerts $31.86 -4.01 (-11.18%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$30.25▼$34.2050-Day Range$17.03▼$35.8752-Week Range$9.44▼$36.25Volume1.60 million shsAverage Volume1.17 million shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$39.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 4D Molecular Therapeutics alerts: Email Address 4D Molecular Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside23.8% Upside$39.44 Price TargetShort InterestBearish17.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 4 Articles This WeekInsider TradingSelling Shares$15.04 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.97) to ($3.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.93 out of 5 starsMedical Sector845th out of 938 stocksBiological Products, Except Diagnostic Industry142nd out of 152 stocks 2.4 Analyst's Opinion Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.44, 4D Molecular Therapeutics has a forecasted upside of 23.8% from its current price of $31.86.Amount of Analyst Coverage4D Molecular Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.08% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 1.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FDMT. Previous Next 2.8 News and Social Media Coverage News Sentiment4D Molecular Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 4D Molecular Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,044,230.00 in company stock.Percentage Held by Insiders10.70% of the stock of 4D Molecular Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.97) to ($3.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -11.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -11.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Read More FDMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FDMT Stock News HeadlinesMarch 21, 2024 | insidertrades.comScott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockMarch 28, 2024 | globenewswire.com4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 4, 2024 | globenewswire.com4DMT to Participate in Upcoming Investor ConferencesMarch 2, 2024 | finance.yahoo.com4D Molecular Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 2, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc Reports Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.com4DMT Reports Full Year 2023 Financial Results and Operational HighlightsFebruary 24, 2024 | msn.com4D Molecular Therapeutics (FDMT) Price Target Increased by 47.68% to 50.55March 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 23, 2024 | benzinga.com4D Molecular Therapeutics Stock (NASDAQ:FDMT) Dividends: History, Yield and DatesFebruary 13, 2024 | markets.businessinsider.comBuy Rating on 4D Molecular Therapeutics Backed by Strong Clinical Results and Broad Commercial ProspectsFebruary 12, 2024 | finance.yahoo.comInstitutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growthFebruary 12, 2024 | finance.yahoo.com4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024February 10, 2024 | msn.com4D Molecular Therapeutics Secures Major Financial DealFebruary 8, 2024 | msn.comGoldman reinstates buy rating on 4D Molecular, cites upcoming catalystsFebruary 8, 2024 | finance.yahoo.comChief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics IncFebruary 7, 2024 | markets.businessinsider.comPositive Outlook for 4D Molecular Therapeutics with Buy Rating Amid Advancements in Gene TherapyFebruary 6, 2024 | msn.com4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts ForecastFebruary 6, 2024 | seekingalpha.com4D Molecular Therapeutics Advances Wet AMD Treatment ParadigmFebruary 5, 2024 | reuters.com4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'February 5, 2024 | msn.comWhy Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?February 3, 2024 | finance.yahoo.com4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMDJanuary 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Intuitive Surgical (ISRG), Mach7 Technologies Ltd. (TDMMF)January 29, 2024 | finance.yahoo.com4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment BurdenJanuary 26, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 SharesJanuary 25, 2024 | seekingalpha.com4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024January 23, 2024 | markets.businessinsider.com4DMT Secures FDA RPDD For Aerosolized 4D-710See More Headlines Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FDMT CUSIPN/A CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees147Year FoundedN/APrice Target and Rating Average Stock Price Target$39.44 High Stock Price Target$81.00 Low Stock Price Target$13.00 Potential Upside/Downside+26.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,840,000.00 Net Margins-436.30% Pretax Margin-486.60% Return on Equity-34.14% Return on Assets-31.07% Debt Debt-to-Equity RatioN/A Current Ratio15.65 Quick Ratio15.65 Sales & Book Value Annual Sales$20.72 million Price / Sales74.75 Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book4.32Miscellaneous Outstanding Shares49,778,000Free Float44,452,000Market Cap$1.55 billion OptionableOptionable Beta2.86 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. John F. Milligan Ph.D. (Age 63)Executive Chairman Comp: $150kDr. David H. Kirn M.D. (Age 62)Co-Founder, CEO & Director Comp: $920.97kDr. Fariborz Kamal Ph.D. (Age 61)President & COO Comp: $678.4kDr. Noriyuki Kasahara M.D. (Age 61)Ph.D., Chief Scientific Officer Comp: $13.6kMs. Theresa Janke (Age 49)Co-Founder & Chief of Staff Comp: $652.32kMr. Uneek Mehra (Age 52)Chief Financial & Business Officer Dr. Scott P. Bizily J.D. (Age 51)Ph.D., Chief Legal Officer & Corporate Secretary Dr. Robert Y. Kim M.B.A. (Age 63)M.D., Chief Medical Officer Dr. An Song Ph.D.Chief Development OfficerDr. Alan H. Cohen FAAAAI (Age 63)FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology More ExecutivesKey CompetitorsInhibrxNASDAQ:INBXAmbrx BiopharmaNYSE:AMAMFusion PharmaceuticalsNASDAQ:FUSNAdaptimmune TherapeuticsNASDAQ:ADAPADMA BiologicsNASDAQ:ADMAView All CompetitorsInsiders & InstitutionsScott BizilySold 1,750 sharesTotal: $54,722.50 ($31.27/share)Vanguard Group Inc.Sold 35,618 shares on 3/11/2024Ownership: 3.750%Wellington Management Group LLPBought 7,753 shares on 3/5/2024Ownership: 0.363%Goldman Sachs Group Inc.Bought 658,069 shares on 3/1/2024Ownership: 1.910%Scott BizilySold 1,909 sharesTotal: $57,270.00 ($30.00/share)View All Insider TransactionsView All Institutional Transactions FDMT Stock Analysis - Frequently Asked Questions Should I buy or sell 4D Molecular Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FDMT shares. View FDMT analyst ratings or view top-rated stocks. What is 4D Molecular Therapeutics' stock price target for 2024? 9 Wall Street analysts have issued 1-year price targets for 4D Molecular Therapeutics' shares. Their FDMT share price targets range from $13.00 to $81.00. On average, they expect the company's share price to reach $39.44 in the next twelve months. This suggests a possible upside of 23.8% from the stock's current price. View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts. How have FDMT shares performed in 2024? 4D Molecular Therapeutics' stock was trading at $20.26 at the start of the year. Since then, FDMT stock has increased by 57.3% and is now trading at $31.86. View the best growth stocks for 2024 here. When is 4D Molecular Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FDMT earnings forecast. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.09. The company had revenue of ($0.02) million for the quarter, compared to analysts' expectations of $4.67 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 34.14% and a negative net margin of 436.30%. What ETFs hold 4D Molecular Therapeutics' stock? ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? 4D Molecular Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.37%), Vanguard Group Inc. (3.75%), Novo Holdings A S (3.51%), Goldman Sachs Group Inc. (1.91%), Goldman Sachs Group Inc. (1.91%) and Dimensional Fund Advisors LP (1.63%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FDMT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.